Printer Friendly

Alpha-1 Foundation, AARC cooperate on study to test 5,000 Copd patients for Alpha-1.

Some 5,000 COPD patients will be tested to determine the prevalence of Alpha-1 Antitrypsin Deficiency (Alpha-1) in a study marking a major cooperative effort between the Alpha-1 Foundation and the American Association for Respiratory Care (AARC).

The principal investigator is Robert A. Sandhaus, MD, PhD, of the Division of Pulmonary Medicine, National Jewish Medical and Research Center in Denver. Sandhaus is also the Clinical Director of the Alpha-1 Foundation.

According to Sandhaus, "If the current literature is correct, the study should identify about 50 to 100 individuals who are unaware they have COPD due to Alpha-1. In addition, the study should identify about 300 people who are carrying a single abnormal Alpha-1 gene. All will be counseled about the potential risk to their children and family members."

Sandhaus points to an intriguing possibility. "If this study confirms what much smaller studies have suggested about Alphas hidden in the COPD population, there could be as many as 400,000 individuals in the US who have lung disease due to Alpha-1 and don't know it."
COPYRIGHT 2008 Focus Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:INDUSTRY NEWS
Publication:FOCUS: Journal for Respiratory Care & Sleep Medicine
Date:Jan 1, 2008
Words:174
Previous Article:Embla Systems in collaboration with Beth Israel Deaconess Medical Center to develop Cardio-Pulmonary Coupling technology.
Next Article:Nspire Health announces Hdpft[TM] - the first commercial high definition Respiratory diagnostic systems platform with accuracy at 3X the standard.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters